Huntsman to Build 100 Million Pound Maleic Anhydride Facility in Geismar

Peter R. Huntsman, President and CEO of Huntsman Corporation, today announced the selection of Huntsman’s Geismar, Louisiana site as the location for the Company’s previously announced new 100 million pound world scale maleic anhydride facility. The Company will commence detailed engineering and reactor procurement immediately. Huntsman has chosen a fast track implementation model that will enable the plant to startup in the 3rd quarter of 2008.

Huntsman Vice President, Tom Fisher, commented, “We want to move as quickly as possible to respond to our customer’s growing requirements and to help ensure the long term supply of maleic anhydride in North America. The Geismar site was chosen after evaluating six possible locations. Huntsman has a world scale MDI manufacturing complex at the site. We are confident that the Geismar site will provide the most attractive economics for the plant due to the feedstock availability and the ability to leverage off existing Huntsman infrastructure currently located at the Geismar site.“

Maleic anhydride is the building block for unsaturated polyester resins used mainly in the production of fiberglass reinforced resins for construction, automotive and marine products. It is also used in formulations for oil additives, food additives, paper chemicals, epoxies, as well as other applications. Huntsman is a leading global producer of maleic anhydride and currently has the annual capacity to produce 240 million pounds at its Pensacola, Florida facility. Huntsman also owns a 50% interest in a joint venture in Moers, Germany that currently has an annual capacity of 125 million pounds.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.